AUTHORS
Lauren Appell, MD, MS, Kevin Tharappel, MBBS2, Kaylee Johnson3, Andrew Brown, PhD4, Jason Farrar, MD5, Joana Mack, MD6
AFFILIATIONS
1 Arkansas Children's Hospital, Little Rock, Arkansas, United States, University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
2 Arkansas Children's Hospital, Little Rock, Arkansas, United States, University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
3 University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
4 Arkansas Children's Hospital, Little Rock, Arkansas, United States, University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
5 Arkansas Children's Hospital, Little Rock, Arkansas, United States, University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
6 Arkansas Children's Hospital, Little Rock, Arkansas, United States, University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
ABSTRACT
Background: Blinatumomab, a bispecific T-cell engager targeting CD3/CD19, is now part of frontline therapy for most pediatric patients with B-cell acute lymphoblastic leukemia (B-ALL). This drug depletes all CD19+ B cells, including memory B cells critical for vaccine-induced humoral immunity, with hypogammaglobulinemia reported in ≥20% of treated patients. For CD19-directed CAR T-cell therapy, which shares the same target and produces analogous B-cell aplasia, international transplant and oncology authorities recommend waiting approximately 6 months after infusion before giving non-live vaccines, on the premise that responses are unreliable until B cells recover. Whether a similar approach to revaccination timing applies after blinatumomab is unknown. Existing infectious disease and oncology guidance for revaccination after childhood leukemia therapy predates the widespread use of B-cell-targeted immunotherapy in frontline pediatric B-ALL and does not address blinatumomab exposure.
Methods: This is a retrospective case-control analysis of vaccine-induced immunity in patients aged 1–21 years treated for B-ALL or B-lymphoblastic lymphoma at Arkansas Children's Hospital and Arkansas Children's Northwest. Cases received ≥1 cycle of blinatumomab during frontline therapy; controls did not receive blinatumomab as part of their treatment regimen. Patients with relapsed/refractory disease, prior transplant, or cellular therapy were excluded. Serum titers to tetanus, Haemophilus influenzae type b (Hib), hepatitis B, Streptococcus pneumoniae (23 serotypes), varicella zoster virus, and measles were obtained as part of routine post-therapy immune reconstitution assessment, together with quantitative IgG and peripheral CD19+ and CD20+ B-cell counts. Non-protection was defined by the reporting laboratory's seroprotection threshold for each antigen, and pneumococcal non-protection as lack of protective titers to >70% of the 23 serotypes tested.
Results: Of 35 patients, 19 were blinatumomab-exposed cases and 16 were controls. Loss of seroprotection was widespread in both groups and was not greater among blinatumomab recipients. Pneumococcal immunity was uniformly absent: 19 (100%) cases and 16 (100%) controls lacked protective titers to >70% of 23 serotypes. Non-protection in cases vs. controls was 6 (32%) vs. 10 (63%) for hepatitis B, 7 (37%) vs. 6 (38%) for measles, 10 (53%) vs. 10 (63%) for varicella, 2 (11%) vs. 3 (19%) for tetanus, and 6 (32%) vs. 6 (38%) for Hib; for every antigen, the proportion lacking protection was equal to or higher in controls than in blinatumomab-exposed cases. Mean IgG was 654 mg/dL (range 70–1354) in cases vs. 827 mg/dL (392–1430) in controls. Mean peripheral B-cell counts at the time of testing were higher in cases than controls (CD19+ 145 cells/µL, range 0–550, vs. 58, range 8–139; CD20+ 156, range 0–550, vs. 51, range 8–132), indicating that blinatumomab-exposed patients had recovered circulating B cells. No patient in either group retained protection across all antigens.
Conclusions: Loss of vaccine-derived humoral immunity after frontline pediatric B-ALL therapy was profound and near-universal in both groups, with complete loss of pneumococcal protection and non-protection reaching 63% for hepatitis B, 63% for varicella, and 38% for measles. Blinatumomab exposure conferred no additional serologic deficit, and B-cell counts had recovered in exposed patients, suggesting the prolonged aplasia seen after CD19 CAR T-cell therapy does not apply. These alarmingly high rates leave a growing survivor population susceptible to vaccine-preventable disease and indicate the critical questions are not blinatumomab-specific: when revaccination should occur, whether B-cell and immunoglobulin recovery should guide that timing, and how durable the resulting seroconversion is. Prospective evaluation is ongoing to address these questions directly.
DISCLOSURES
Kevin Tharappel, MBBS: No relevant conflicts of interest to declare.